Krystal Biotech, Inc.

Form 483 issued January 30, 2025 · Pittsburgh, Pennsylvania

Inspection
Jan 22 – Jan 30, 2025
Observations
2
Pages
4
FEI number
3013498720

In short: On January 30, 2025, FDA issued a Form 483 with 2 observations to Krystal Biotech, Inc. in Pittsburgh, Pennsylvania (FEI 3013498720) after an inspection that ran Jan 22 – Jan 30, 2025. The investigators were Lewis K. Antwi and Richard L. Bartlett. Most observations concern quality system and materials; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

Quality system and materials account for 2 of 2 observations.

Quality system1
Materials1

Most cited: 21 CFR 211.192 (1×) · 211.84 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    There is a failure to thoroughly review any unexplained discrepancy whether or not the batch…

  2. 02

    Failure to check the reliability of Certificate of Analysis…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Krystal Biotech, Inc.?

FDA listed 2 observations on this Form 483, mostly about quality system and materials. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Krystal Biotech, Inc.?

Lewis K. Antwi and Richard L. Bartlett are named on this Form 483, for the inspection of Jan 22 – Jan 30, 2025. Each investigator has a profile showing what they cite most.

When was Krystal Biotech, Inc. inspected by FDA?

The inspection ran Jan 22 – Jan 30, 2025, and the Form 483 is dated January 30, 2025.

How do I get the full Form 483 for Krystal Biotech, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free